Therefore, in the near future, we will witness the results of three important phase III trials of T-DXd, BAY2927088, and zongertinib controlled with SoC (chemotherapy plus ICI) in the treatment of naïve HER2 MUT NSCLC patients. Here, ERBB2 is linked to non-small cell lung carcinoma.